Tempus AI Acquires Cancer-Monitoring Firm Personalis for $1.5 Billion
Tempus AI has agreed to acquire Personalis in a $1.5 billion deal, offering shareholders $16.25 per share as part of a stock-based transaction with an option to pay up to half in cash. The acquisition aims to expand Tempus' capabilities through Personalis’ NeXT Personal test for monitoring cancer recurrence using circulating tumor DNA.